Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EMD Serono Establishes Immuno-Oncology Platform | Contract Pharma

What are you searching for?

Sign in
Breaking News

EMD Serono Establishes Immuno-Oncology Platform

Aims to advance innovative in cancer therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, has established a dedicated immuno-oncology innovation platform integrating research, early development and biomarker strategies. The new platform will focus on developing therapies that leverage the immune system’s natural ability to fight tumors, and work in combination with existing and future therapies.

The new immuno-oncology platform includes therapeutic cancer vaccines, cancer stem cells, and immunotolerance. The portfolio comprises candidates in early clinical development and preclinical molecules including a monoclonal antibody targeting PD-L1 (programmed cell death ligand, NHS-IL12, a cancer immunotherapy targeting IL-12 to the necrotic regions of tumors, and NHS-IL2, targeting IL-2 to the necrotic regions of tumors.

“Our goal is to develop leading immunotherapies that work in combination with other therapeutic modalities, understanding that attacking multiple cancer targets simultaneously increases the possibility of therapeutic success,” said Helen Sabzevari, head of Immuno-Oncology, Global Research and Early Development at Merck Serono, a division of Merck KGaA, Darmstadt, Germany. “We are committed to delivering on the promise of immuno-oncology by combining creative thinking with strong research and clinical excellence, and, more importantly, by keeping patient needs at the heart of our efforts.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters